Letter to the EditorSevere ataxic polyneuropathy associated with chronic levodopa use in Parkinson's disease
Section snippets
Acknowledgements
None.
References (5)
- et al.
Is chronic levodopa therapy associated with distal symmetric polyneuropathy in Parkinson's disease?
Parkinsonism Relat Disord
(2013) - et al.
Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery
Park Rel Disord
(2013)
Cited by (17)
An overview of pain in Parkinson's disease
2020, Clinical Parkinsonism and Related DisordersCitation Excerpt :Patients with PD have a high prevalence of symmetrical neuropathy, predominantly in sensory axons [36]. The risk of polyneuropathy has been reported to be increased in patients taking high doses of levodopa [37,38]. Kaur et al. described a patient with pre-existing polyneuropathy that developed acute neuropathic pain, related to a treatment of levodopa-carbidopa intestinal gel (LCIG) infusion [39].
Peripheral neuropathy in idiopathic Parkinson's disease: A systematic review
2017, Journal of the Neurological SciencesCitation Excerpt :Inflammatory infiltrates of CD8-immunoreactive T-cells were absent [29]. Evidence of inflammatory changes (perivascular lymphocytic cuffing) had been found in sural nerve biopsies in one of 3 patients reported by Kimber et al. [30] when mild inflammatory infiltration lymphocytes in one out of 2 patients reported by Cáceres-Redondo et al. [31]. Vital et al. conducted a pathological study of peripheral nerves from patients with PN and demonstrated intra-axonal ubiquitin aggregates were more numerous in the patients with PN and PD compared to patients without PD [32].
The peripheral nerve involvement in Parkinson Disease: A multifaceted phenomenon
2016, Parkinsonism and Related DisordersLevodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition
2016, Parkinsonism and Related DisordersCitation Excerpt :Electrophysiologic data, TNSr, UPDRS III and UPDRS item 30 scores are reported in Table 2. Several studies reported the frequent occurrence of PN during long-term LD treatment [1–6]. In 2013 our previous large multicenter study, conducted on about 500 pts, we stratified the risk of neuropathy based on the length of LD exposure showing a significant PN prevalence in patients taking LD for a longer period (almost 20% in patients with LD exposure > 3 years); neuropathy was also associated with the cumulative dose of LD, high Hcy and reduced VB12 serum levels [4].
Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies
2014, Parkinsonism and Related DisordersCitation Excerpt :Whilst long term follow-up studies confirmed CLDII efficacy in controlling motor symptoms, in 2007 the first case of acute PN during CLDII was reported [49] (Table 2). In the following years, along with the increase in CLDII use, there have been other reports of acute/subacute PN, inconstantly associated with signs of encephalopathy [42–46] (Table 2). Some of these acute conditions were associated with severe weight loss and low micronutrients blood levels (vitamin B1, B6, B12, and folate) and improved after CLDII withdrawal with switch back to oral therapy and vitamin supplementation [35,42,50–52].
Acute motor axonal polyneuropathy in one parkinsonian patient receiving moderate dosage of oral levodopa
2021, Neurological Sciences